Powered by

Leap Therapeutics Reports Third Quarter 2020 Financial Results

Nov 12, 2020 - PR Newswire

PR Newswire

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the third quarter ended September 30, 2020.

Leap Third Quarter Highlights:

First patient dosed in Phase 2a study of Leap's anti-Dickkopf-1 (DKK1) antibody DKN-01 in combination with tislezumab, BeiGene's anti-PD-1 antibody, for the treatment of metastatic gastric or gastroesophageal junction (G/GEJ) canc...